Optinose Stock Price, News & Analysis

Optinose (NASDAQ: OPTN) has completed recruitment for its second Phase 3b trial of XHANCE (fluticasone propionate) nasal spray targeting chronic sinusitis (CS), a condition affecting 30 million adults in the U.S. The company anticipates topline results from the first trial in Q1 2022 and from the second in Q2 2022, aiming for FDA approval of XHANCE as the first drug treatment for CS. This approval could significantly expand business opportunities and provide relief for many patients.

Optinose (NASDAQ:OPTN) has announced that CEO Peter Miller will present a company overview and update at the Cantor Virtual Global Healthcare Conference on September 28, 2021, at 8:40 a.m. ET. Interested parties can access the live webcast on the Investors page of the Optinose website, with a replay available for 30 days post-event. The company specializes in providing solutions for patients treated by ENT and allergy specialists.

OptiNose, Inc. (NASDAQ:OPTN) announced the grant of non-qualified stock option awards to seven new employees. A total of 60,000 shares were awarded to incentivize employment acceptance. The options were granted outside the company’s 2010 Stock Incentive Plan, adhering to Nasdaq Rule 5635(c)(4). Exercise prices were set at $2.51 and $2.57, corresponding to closing prices on grant dates of August 16 and 23, 2021. These options have a 10-year term and will vest over four years, with 25% vesting after one year and the remaining in monthly installments.

Optinose reported a 79% increase in XHANCE net revenue for Q2 2021, totaling $18.4 million, compared to Q2 2020. Total prescriptions rose by 33%, and new prescriptions surged by 55%. The company has completed enrollment in the first pivotal chronic sinusitis clinical trial and aims for at least $80 million in XHANCE revenue for 2021. Net loss for Q2 2021 was $23.5 million ($0.44 per share). Optinose has cash equivalents of $93.9 million as of June 30, 2021.

Optinose (NASDAQ:OPTN) announced the successful completion of recruitment in its first pivotal clinical trial for XHANCE, a nasal spray aimed at treating chronic sinusitis, with top-line results expected in Q1 2022. This milestone brings the company closer to potentially offering the first FDA-approved drug treatment for the estimated 30 million chronic sinusitis sufferers in the U.S. The company is focusing its efforts on completing the second pivotal trial by year-end. CEO Peter Miller emphasized the significant market potential for XHANCE with successful development.

Optinose reported preliminary XHANCE net revenue of $18.4 million for Q2 2021, marking a 79% increase year-over-year and a 67% increase from Q1 2021. XHANCE prescriptions rose 33% to 82,900, with revenue per prescription increasing 35% to $221. The company maintains its 2021 revenue guidance of at least $80 million. Full financial results will be disclosed on August 11, 2021, during a scheduled conference call.

Optinose (NASDAQ:OPTN) announced the publication of a new treatment algorithm for chronic rhinosinusitis with nasal polyps in the International Forum of Allergy & Rhinology. The algorithm promotes Exhalation Delivery System-fluticasone (EDS-FLU) as a key treatment step, simplifying the confusion surrounding available treatment options. With over 85% of patients frustrated by standard steroids, EDS-FLU aims to provide better symptom relief. This algorithm is expected to enhance care quality and guide clinical decision-making amidst increasing treatment choices.

Optinose (NASDAQ:OPTN), a pharmaceutical company specializing in ENT and allergy treatments, has announced that CEO Peter Miller will present a company overview at the Jefferies Virtual Healthcare Conference on June 3, 2021, at 3:30 p.m. ET. The public can access the presentation via the Investors page on the Optinose website. Additionally, a replay of the webcast will be available for 30 days post-event. For more details about Optinose and its services, visit www.optinose.com.